CCN4 and glioblastoma: Collectively, these data demonstrate that inhibition of Wnt/β-catenin-WISP1 signaling by CA disrupts GSC maintenance, impairs M2 TAM survival, and potently suppresses GBM tumor growth, indicating that targeting this pathway may effectively improve GBM treatment.